Table 3.
Summary of OR for XRCC3 Thr241Met polymorphism and bladder cancer risk
| Subgroup | Number of comparisons | C/C vs T/T | (C/C+C/T) vs T/T | C/C vs (C/T+T/T) |
|---|---|---|---|---|
| Ethnicity | ||||
| Caucasian | 8 | 0.954 (0.916–0.995)* | 0.980 (0.960–1.000)** | 0.953 (0.895–1.013) |
| Design | ||||
| Hospital‐based study | 5 | 0.954 (0.907–1.003) | 0.985 (0.960–1.011) | 0.920 (0.852–0.994)*** |
| Population‐based study | 4 | 0.965 (0.913–1.021) | 0.978 (0.951–1.005) | 1.002 (0.921–1.090) |
| Overall | 9 | 0.959 (0.924–0.996)**** | 0.982 (0.963–1.000)***** | 0.958 (0.905–1.014) |
*P = 0.027; **P = 0.050; ***P = 0.034; ****P = 0.029; *****P = 0.050. OR, odds ratio; XRCC3, X‐ray repair cross‐complementing group 3.